Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

2.1 Atezolizumab (Tecentriq, Roche) received a promising innovative medicine designation in November 2018 and a positive opinion from the Early Access to Medicines Scheme in June 2019.

Having received a marketing authorisation in other cancer indications in 2017, on 26 July 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product atezolizumab. The CHMP adopted a new indication as follows: 'Tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small-cell lung cancer (ES-SCLC)'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of atezolizumab is £3,807.69 per 1,200 mg vial (excluding VAT; BNF online, accessed April 2019). The mean treatment cost of a course of treatment for a patient with ES‑SCLC is £32,798.39 for atezolizumab (at list price), £76.18 for carboplatin and £30.89 for etoposide.

The company has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.